那他珠单抗停药后富马酸二甲酯、芬戈莫德与奥瑞珠单抗的比较
这项观察性队列研究基于MSBase登记数据,纳入1386例停用那他珠单抗后换用富马酸二甲酯、芬戈莫德或奥瑞珠单抗的复发缓解型多发性硬化患者。奥瑞珠单抗的年化复发率最低(0.06),芬戈莫德和富马酸二甲酯的年化复发率分别为0.26和0.27,且奥瑞珠单抗首次复发时间最长、停药率最低。
要点
- 奥瑞珠单抗年化复发率0.06,低于芬戈莫德的0.26和富马酸二甲酯的0.27。
- 与奥瑞珠单抗相比,芬戈莫德首次复发HR为4.02,富马酸二甲酯为3.70。
- 芬戈莫德较奥瑞珠单抗残疾累积风险高49%,残疾改善率无显著差异。
核心结论
- 在停用那他珠单抗后换用富马酸二甲酯、芬戈莫德或奥瑞珠单抗的复发缓解型多发性硬化患者中,奥瑞珠单抗与最低的年化复发率和停药率以及最长的首次复发时间相关。
研究设计与样本
- 这项观察性队列研究收集MSBase登记处2010年6月15日至2021年7月6日的数据,中位随访2.7年。
- 研究纳入使用那他珠单抗6个月或更长时间、停药后3个月内换用富马酸二甲酯、芬戈莫德或奥瑞珠单抗的复发缓解型多发性硬化患者,排除无基线数据者。
- 共纳入1386例患者(平均[SD]年龄41.3[10.6]岁;女性990例[71%]),换用富马酸二甲酯138例(9.9%)、芬戈莫德823例(59.4%)、奥瑞珠单抗425例(30.7%)。
主要发现
- 奥瑞珠单抗的年化复发率为0.06(95%CI 0.04-0.08),芬戈莫德为0.26(95%CI 0.12-0.48),富马酸二甲酯为0.27(95%CI 0.12-0.56)。
- 芬戈莫德与奥瑞珠单抗的年化复发率比值为4.33(95%CI 3.12-6.01),富马酸二甲酯与奥瑞珠单抗为4.50(95%CI 2.89-7.03)。
- 与奥瑞珠单抗相比,芬戈莫德首次复发风险HR为4.02(95%CI 2.83-5.70),富马酸二甲酯为3.70(95%CI 2.35-5.84)。
- 与奥瑞珠单抗相比,芬戈莫德停药风险HR为2.57(95%CI 1.74-3.80),富马酸二甲酯为4.26(95%CI 2.65-6.84)。
- 芬戈莫德较奥瑞珠单抗残疾累积风险高49%;芬戈莫德与奥瑞珠单抗的残疾改善率无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Natalizumab cessation is associated with a risk of rebound disease activity. It is important to identify the optimal switch disease-modifying therapy strategy after natalizumab to limit the risk of severe relapses. OBJECTIVES: To compare the effectiveness and persistence of dimethyl fumarate, fingolimod, and ocrelizumab among patients with relapsing-remitting multiple sclerosis (RRMS) who discontinued natalizumab. DESIGN, SETTING, AND PARTICIPANTS: In this observational cohort study, patient data were collected from the MSBase registry between June 15, 2010, and July 6, 2021. The median follow-up was 2.7 years. This was a multicenter study that included patients with RRMS who had used natalizumab for 6 months or longer and then were switched to dimethyl fumarate, fingolimod, or ocrelizumab within 3 months after natalizumab discontinuation. Patients without baseline data were excluded from the analysis. Data were analyzed from May 24, 2022, to January 9, 2023. EXPOSURES: Dimethyl fumarate, fingolimod, and ocrelizumab. MAIN OUTCOMES AND MEASURES: Primary outcomes were annualized relapse rate (ARR) and time to first relapse. Secondary outcomes were confirmed disability accumulation, disability improvement, and subsequent treatment discontinuation, with the comparisons for the first 2 limited to fingolimod and ocrelizumab due to the small number of patients taking dimethyl fumarate. The associations were analyzed after balancing covariates using an inverse probability of treatment weighting method. RESULTS: Among 66 840 patients with RRMS, 1744 had used natalizumab for 6 months or longer and were switched to dimethyl fumarate, fingolimod, or ocrelizumab within 3 months of natalizumab discontinuation. After excluding 358 patients without baseline data, a total of 1386 patients (mean [SD] age, 41.3 [10.6] years; 990 female [71%]) switched to dimethyl fumarate (138 [9.9%]), fingolimod (823 [59.4%]), or ocrelizumab (425 [30.7%]) after natalizumab. The ARR for each medication was as follows: ocrelizumab, 0.06 (95% CI, 0.04-0.08); fingolimod, 0.26 (95% CI, 0.12-0.48); and dimethyl fumarate, 0.27 (95% CI, 0.12-0.56). The ARR ratio of fingolimod to ocrelizumab was 4.33 (95% CI, 3.12-6.01) and of dimethyl fumarate to ocrelizumab was 4.50 (95% CI, 2.89-7.03). Compared with ocrelizumab, the hazard ratio (HR) of time to first relapse was 4.02 (95% CI, 2.83-5.70) for fingolimod and 3.70 (95% CI, 2.35-5.84) for dimethyl fumarate. The HR of treatment discontinuation was 2.57 (95% CI, 1.74-3.80) for fingolimod and 4.26 (95% CI, 2.65-6.84) for dimethyl fumarate. Fingolimod use was associated with a 49% higher risk for disability accumulation compared with ocrelizumab. There was no significant difference in disability improvement rates between fingolimod and ocrelizumab. CONCLUSION AND RELEVANCE: Study results show that among patients with RRMS who switched from natalizumab to dimethyl fumarate, fingolimod, or ocrelizumab, ocrelizumab use was associated with the lowest ARR and discontinuation rates, and the longest time to first relapse.
引用
- Zhu C, Kalincik T, Horakova D, et al. Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation. JAMA Neurol. 2023. PMID: 37273217. doi:10.1001/jamaneurol.2023.1542
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。